Alumis Inc. (ALMS) CMO sells 2,447 shares in required tax sell-to-cover

Rhea-AI Filing Summary

ALUMIS INC.’s Chief Medical Officer, Jorn Drappa, reported a mandatory sale of 2,447 shares of common stock on August 3, 2026 at a weighted average price of $26.37 per share, in multiple trades between $25.54 and $26.42. The sale was executed under company policy as a sell-to-cover transaction to satisfy tax obligations arising from the vesting and settlement of restricted stock units granted on July 29, 2025, and is described as not a discretionary sale. Following these sales, Drappa directly holds 56,892 shares of Alumis common stock.

Insider Trade Summary

Net Seller: 2,447 shares

Net Sell 1 txn

Insider Drappa Jorn

Role Chief Medical Officer

Sold 2,447 shs ($65K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	2,447	$26.37	$65K

Holdings After Transaction: Common Stock — 56,892 shares (Direct)

Footnotes (2)

1. F1. The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person.
2. F2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.54 to $26.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 2,447 shares Weighted average sale price: $26.37 per share Sale price range: $25.54–$26.42 per share +2 more

5 metrics

Shares sold 2,447 shares Common stock sold on August 3, 2026 by the CMO

Weighted average sale price $26.37 per share Average price for the 2,447 shares sold

Sale price range $25.54–$26.42 per share Range of prices for multiple sale transactions

Shares held after sale 56,892 shares Direct common stock holdings of the CMO after the transaction

RSU grant date July 29, 2025 Date of restricted stock units whose vesting triggered tax sell-to-cover

Key Terms

sell-to-cover, restricted stock units, weighted average sale price

3 terms

sell-to-cover financial

"policy requiring sell-to-cover to satisfy tax obligations"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

restricted stock units financial

"vesting and settlement of restricted stock units granted on July 29, 2025"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"reported price in Column 4 is a weighted average sale price"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 06:37 PM Accepted by SEC EDGAR 08/05/2026 - 06:36 PM Learn about SEC filing dates

FAQ

What insider transaction did Alumis (ALMS) disclose in this Form 4?

Alumis (ALMS) disclosed that Chief Medical Officer Jorn Drappa sold 2,447 common shares on August 3, 2026. The transaction was a sell-to-cover sale required to pay taxes linked to the vesting and settlement of previously granted restricted stock units.

How many Alumis (ALMS) shares did the CMO sell and at what price?

The CMO of Alumis (ALMS) sold 2,447 shares of common stock at a weighted average price of $26.37 per share. The shares were sold in multiple transactions at prices ranging from $25.54 to $26.42 per share, as disclosed in the Form 4 footnote.

Was the Alumis (ALMS) insider sale by the CMO discretionary?

The filing states the sale by Alumis (ALMS) CMO was not discretionary. It was carried out pursuant to the company’s policy requiring sell-to-cover transactions to satisfy tax obligations from the vesting and settlement of restricted stock units granted on July 29, 2025.

How many Alumis (ALMS) shares does the CMO hold after this transaction?

After the reported transaction, the Alumis (ALMS) Chief Medical Officer directly holds 56,892 shares of common stock. This post-transaction holding reflects the position remaining following the 2,447-share sale executed to cover tax obligations related to vested restricted stock units.

What was the trading range for the Alumis (ALMS) shares sold by the CMO?

The Alumis (ALMS) shares sold by the CMO traded between $25.54 and $26.42 per share. The reported $26.37 figure is a weighted average sale price, with more detailed per-trade pricing available upon request from the company or the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Drappa Jorn

(Last) (First) (Middle)

C/O ALUMIS INC.

280 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ALUMIS INC. [ ALMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		S		2,447(1)	D	$26.37(2)	56,892	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person.

2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.54 to $26.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Sanam Pangali, Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)